Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.29 -2.6%	$0.40	$0.14 ▼ $1.27	$11.92M	1.79	5.96 million shs	408,575 shs
CYCC Cyclacel Pharmaceuticals	$8.89 -0.1%	$7.50	$3.08 ▼ $597.60	$14.05M	0.08	766,756 shs	89,456 shs
NERV Minerva Neurosciences	$1.82 +0.3%	$1.83	$1.15 ▼ $3.00	N/A	-0.32	22,545 shs	6,800 shs
VRAX Virax Biolabs Group	$0.75 -0.4%	$0.88	$0.72 ▼ $9.00	$3.24M	1.66	189,266 shs	42,830 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	+4.64%	-4.00%	-35.00%	+64.24%	-70.99%
CYCC Cyclacel Pharmaceuticals	-4.09%	+20.11%	+168.88%	-73.03%	-97.31%
NERV Minerva Neurosciences	+1.40%	-0.60%	+1.69%	+16.40%	-36.71%
VRAX Virax Biolabs Group	-3.29%	-4.46%	-18.98%	-29.23%	-41.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARM Carisma Therapeutics	2.9634 of 5 stars	3.4	5.0	0.0	2.6	0.8	0.6
CYCC Cyclacel Pharmaceuticals	1.7494 of 5 stars	0.0	4.0	0.0	4.4	2.5	0.0
NERV Minerva Neurosciences	4.1373 of 5 stars	3.0	3.0	4.6	3.3	0.0	1.3
VRAX Virax Biolabs Group	3.4996 of 5 stars	3.5	5.0	0.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARM Carisma Therapeutics	2.71	Moderate Buy	$1.93	585.05% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
NERV Minerva Neurosciences	2.00	Hold	$5.00	173.22% Upside
VRAX Virax Biolabs Group	3.00	Buy	$3.00	297.35% Upside

Current Analyst Ratings Breakdown

Latest VRAX, CARM, CYCC, and NERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/8/2025	CARM Carisma Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$1.00
7/15/2025	CARM Carisma Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARM Carisma Therapeutics	$10.77M	1.09	N/A	N/A	($1.10) per share	-0.26
CYCC Cyclacel Pharmaceuticals	$40K	337.13	N/A	N/A	($58.87) per share	-0.14
NERV Minerva Neurosciences	N/A	N/A	$0.22 per share	8.42	($3.67) per share	N/A
VRAX Virax Biolabs Group	$6.33K	517.80	N/A	N/A	$1.26 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARM Carisma Therapeutics	-$60.48M	-$1.56	N/A	N/A	N/A	-254.28%	N/A	-211.28%	8/14/2025 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$839.58	N/A	∞	N/A	N/A	-3,648.09%	-155.99%	N/A
NERV Minerva Neurosciences	$1.44M	$0.82	2.23	N/A	N/A	N/A	-20.68%	15.73%	8/19/2025 (Estimated)
VRAX Virax Biolabs Group	-$6.06M	N/A	0.00	∞	N/A	N/A	N/A	N/A	10/1/2025 (Estimated)

Latest VRAX, CARM, CYCC, and NERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q2 2025	NERV Minerva Neurosciences	-$0.95	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	CARM Carisma Therapeutics	-$0.10	N/A	N/A	N/A	$3.75 million	N/A
8/13/2025	Q2 2025	CYCC Cyclacel Pharmaceuticals	-$72.00	-$0.98	+$71.02	-$0.98	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARM Carisma Therapeutics	N/A	0.48	0.48
CYCC Cyclacel Pharmaceuticals	N/A	5.60	5.60
NERV Minerva Neurosciences	N/A	9.21	9.21
VRAX Virax Biolabs Group	N/A	7.27	7.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARM Carisma Therapeutics	44.27%
CYCC Cyclacel Pharmaceuticals	23.58%
NERV Minerva Neurosciences	34.56%
VRAX Virax Biolabs Group	8.61%

Insider Ownership

Company	Insider Ownership
CARM Carisma Therapeutics	6.90%
CYCC Cyclacel Pharmaceuticals	51.20%
NERV Minerva Neurosciences	8.60%
VRAX Virax Biolabs Group	45.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARM Carisma Therapeutics	20	41.79 million	38.91 million	No Data
CYCC Cyclacel Pharmaceuticals	14	1.58 million	773,000	Optionable
NERV Minerva Neurosciences	9	N/A	N/A	Not Optionable
VRAX Virax Biolabs Group	5	4.34 million	2.38 million	Not Optionable

VRAX, CARM, CYCC, and NERV Headlines

Recent News About These Companies

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

July 29, 2025 | prnewswire.com

Virax Biolabs Group Limited (VRAX) Latest Stock News & Headlines ...

July 22, 2025 | finance.yahoo.com

Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

July 20, 2025 | finanznachrichten.de

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

July 18, 2025 | prnewswire.com

HC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy Recommendation

March 31, 2025 | msn.com

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

March 31, 2025 | benzinga.com

Virax Biolabs Launches Clinical Study on T Cell Dysfunction

March 18, 2025 | msn.com

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

March 18, 2025 | prnewswire.com

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

March 13, 2025 | prnewswire.com

Virax Biolabs to Present at 19th World Immune Regulation Meeting

March 5, 2025 | prnewswire.com

Virax Biolabs Aligns with US Health Department on Vaccine Transparency

February 25, 2025 | tipranks.com

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

February 25, 2025 | prnewswire.com

Cosmos Health expands distribution of Avian Influenza kits

January 23, 2025 | msn.com

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

January 23, 2025 | accessnewswire.comA

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

January 13, 2025 | accesswire.comA

Virax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?

December 19, 2024 | bovnews.comB

Virax Biolabs Announces Strategic Goals and Developments for 2025

December 18, 2024 | markets.businessinsider.com

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

December 17, 2024 | prnewswire.com

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

December 10, 2024 | prnewswire.com

Virax Biolabs Sees Asset Growth Amid Financial Loss

November 22, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX, CARM, CYCC, and NERV Company Descriptions

Carisma Therapeutics NASDAQ:CARM

$0.29 -0.01 (-2.63%)

Closing price 04:00 PM Eastern

Extended Trading

$0.30 +0.01 (+3.40%)

As of 04:24 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$8.89 -0.01 (-0.11%)

Closing price 04:00 PM Eastern

Extended Trading

$8.80 -0.10 (-1.07%)

As of 04:27 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Minerva Neurosciences NASDAQ:NERV

$1.82 +0.01 (+0.28%)

Closing price 03:48 PM Eastern

Extended Trading

$1.82 0.00 (0.00%)

As of 04:10 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Virax Biolabs Group NASDAQ:VRAX

$0.75 0.00 (-0.43%)

As of 03:57 PM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time